Vimarsana
Biggest News Aggregation in the World

Page 12 - Nasdaq Pcvx News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nasdaq Pcvx. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nasdaq Pcvx Today - Breaking & Trending Today

Vaxcyte (NASDAQ:PCVX) Earns Outperform Rating from Analysts at TD Cowen - Vimarsana News

Vaxcyte (NASDAQ:PCVX) Earns Outperform Rating from Analysts at TD Cowen

TD Cowen began coverage on shares of Vaxcyte (NASDAQ:PCVX – Get Rating) in a report issued on Tuesday morning, Briefing.com reports. The firm issued an outperform rating on the stock. A number of other research analysts also recently commented on the company. Needham & Company LLC restated a buy rating and set a $58.00 price […]

Source: wkrb13.com
Vaxcyte Announces Closing of $575 Million Public Offering - Vimarsana News

Vaxcyte Announces Closing of $575 Million Public Offering

SAN CARLOS, Calif., April 21, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering...

Vaxcyte (NASDAQ:PCVX) Shares Gap Up to $36.50 - Vimarsana News

Vaxcyte (NASDAQ:PCVX) Shares Gap Up to $36.50

Vaxcyte, Inc. (NASDAQ:PCVX – Get Rating)’s stock price gapped up before the market opened on Monday . The stock had previously closed at $36.50, but opened at $42.04. Vaxcyte shares last traded at $42.76, with a volume of 677,688 shares. Analysts Set New Price Targets A number of brokerages recently issued reports on PCVX. Guggenheim […]

Vaxcyte to Host Webcast and Conference Call to Discuss - Vimarsana News

Vaxcyte to Host Webcast and Conference Call to Discuss

SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering...

Vaxcyte (NASDAQ:PCVX) Shares Gap Down on Analyst Downgrade - Vimarsana News

Vaxcyte (NASDAQ:PCVX) Shares Gap Down on Analyst Downgrade

Vaxcyte, Inc. (NASDAQ:PCVX – Get Rating) gapped down prior to trading on Tuesday after Guggenheim lowered their price target on the stock from $66.00 to $65.00. The stock had previously closed at $42.30, but opened at $40.00. Guggenheim currently has a buy rating on the stock. Vaxcyte shares last traded at $38.74, with a volume […]